Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vivitrex (Alkermes/Cephalon).

Christine E Heading1

  • 1Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle-upon-Tyne NE3 3PW, UK. moore11@globalnet.co.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|January 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender issues and the pharmacotherapy of substance abuse.

IDrugs : the investigational drugs journal·2008
Same author

Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction.

Current opinion in investigational drugs (London, England : 2000)·2007
Same author

Conus toxins: targets and properties.

IDrugs : the investigational drugs journal·2004
Same author

NicVAX (Nabi Biopharmaceuticals).

IDrugs : the investigational drugs journal·2003
Same author

Recent advances against substance abuse.

IDrugs : the investigational drugs journal·2003
Same author

TA-CD. Xenova.

IDrugs : the investigational drugs journal·2003

Vivitrex, a sustained-release naltrexone injection, is being developed for monthly treatment of alcoholism and opiate use disorder. The new drug application is currently under Food and Drug Administration review.

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Drug Development

Background:

  • Opioid antagonist naltrexone is used to treat substance use disorders.
  • Current formulations require frequent dosing, impacting adherence.
  • There is a need for long-acting treatments for alcoholism and opiate use disorder.

Purpose of the Study:

  • To describe the development of Vivitrex, a novel injectable formulation of naltrexone.
  • To highlight its potential as a once-monthly treatment for alcoholism and opiate use disorder.

Main Methods:

  • Vivitrex is an injectable, sustained-release formulation.
  • It utilizes naltrexone, an opioid antagonist.
  • Development is being undertaken by Alkermes and Cephalon.

Related Experiment Videos

Main Results:

  • Vivitrex is currently awaiting Food and Drug Administration (FDA) review.
  • The new drug application received Priority Review status in May 2005.

Conclusions:

  • Vivitrex represents a potential advancement in the treatment of alcoholism and opiate use disorder.
  • Its sustained-release, once-monthly formulation may improve treatment adherence and outcomes.